1. Belgium Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Lakefront Biotherapeutics

Lakefront Biotherapeutics

GLPG.AS
Lakefront BiotherapeuticsEU flagEuronext Amsterdam
26.28
EUR
+0.58
- -
1.73BMarket Cap
Lakefront Biotherapeutics
GLPG.AS
(Euronext Amsterdam)

Recent

price

26.28

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
5.04
3.63
5.13
2.66
2.3
1.11
2.83
2.57
5.35
14.49
7.35
3.58
3.67
3.64
4.17
16.88
15.84
Revenue per Share
0.18
-1.25
-0.22
-0.28
1.1
-3.32
1.18
-2.34
-0.56
2.6
-4.69
-1.58
-3.32
3.21
1.12
4.87
7.42
Basic EPS, GAAP
-0.94
-0.68
2.16
-0.21
-2.6
-3.4
5.13
-3.12
-3
54.9
-7.97
-8.58
-8.19
-6.45
-6.08
-4.12
-4.71
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
3.17
1.75
1.68
1.89
3.1
0.23
2.44
0.44
-1.18
3.09
-0.67
-1.15
-3.09
1
2.41
7.66
7.93
Book Value per Share
3.81
2.61
2.69
4.17
6.78
10.18
16.58
20.4
23.23
49.48
40
39.44
35.18
39.43
40.25
49.09
49.38
Tangible Book Value per Share
24
26
27
29
30
36
46
49
52
58
65
66
66
66
66
66
66
Basic Weighted Avg Shares
122
96
136
77
69
40
130
127
279
835
478
234
241
240
276
1,112
1,044
Sales/Revenue/Turnover
1.2
-36.59
-1.54
-21.69
-51.83
-226.09
-8.87
-70.66
-16.89
44.17
-37.37
-73.2
-54.32
-36.82
-68.33
45.08
57.14
Operating Margin (%)
12
12
9
8
5
3
4
4
5
12
19
35
66
44
45
56
- -
Depreciation Expense
4
-33
-6
-8
33
-118
54
-116
-29
150
-305
-103
-218
212
74
321
489
Net Income, GAAP
- -
- -
- -
- -
- -
- -
0.43
- -
- -
- -
- -
- -
- -
170.9
- -
- -
0.59
Effective Tax Rate (%)
3.57
-34.52
-4.2
-10.54
47.88
-299.3
41.7
-91.04
-10.5
17.95
-63.89
-44.04
-90.36
88.31
26.88
28.85
46.83
Profit Margin (%)
71
30
24
61
153
302
903
1,026
1,109
5,294
4,734
4,295
3,714
3,433
3,004
2,927
2,960
Working Capital
1
- -
- -
- -
- -
- -
- -
- -
- -
20
23
20
15
5
8
5
5
LT Debt
149
118
118
167
206
365
759
1,012
1,214
2,876
2,670
2,643
2,526
2,796
2,897
3,236
3,253
Total Equity
- -
- -
- -
- -
- -
- -
-2.03
- -
- -
- -
- -
- -
- -
2.34
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
90.16
- -
- -
- -
- -
- -
- -
-397.34
- -
- -
270.87
Return on Capital (%)
6.57
-53.66
-12.59
-16.32
44.95
-233.52
90.22
-173.17
- -
- -
- -
- -
- -
- -
65.76
96.63
182.59
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
2
2
2
LT Borrowings
- -
- -
- -
LT Finance Leases
6
5
5
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
66
66
66
Market Capitalization
1,920
1,843
1,725

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
3,162
3,079
3,061
Cash, Cash Equivalents & STI
3,050
2,998
2,982
Accounts Receivable, Net
45
10
22
Inventories
23
22
18
Total Current Liabilities
367
153
100
Payables & Accruals
101
34
97
ST Debt
2
2
2
Deferred Revenue
230
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
31.15%
4.11%
11.7%
Free Cash Flow
-275.46%
-10.97%
-32.53%
Net Income, GAAP
-133.45%
23.2%
333.15%
Sales/Revenue/Turnover
77.15%
53.96%
303.5%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
62
78
60
75
276
2025
75
65
71
901
1,112
2026
6
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.37
- -
- -
- -
1.12
2025
-2.33
- -
- -
- -
4.87
2026
0.22
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
NanoSphere Health Sciences Inc. (NSHS.CN)
Mobile Lads Corp. (MOBO)
4D pharma plc (LBPSW)
Fulcrum Therapeutics, Inc. (FULC)
Connect Biopharma Holdings Limited (CNTB)
Amplia Therapeutics Limited (INNMF)
Business
Galapagos NV (GLPG.AS) is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel medicines for inflammatory, fibrotic, and other unmet medical needs. The company offers a pipeline of product candidates including filgotinib, an oral JAK1 inhibitor for rheumatoid arthritis, ulcerative colitis, and Crohn's disease; Jyseleca (filgotinib), approved in Europe and Japan for rheumatoid arthritis and ulcerative colitis; and ziritaxestat (GLPG3970), a novel autotaxin inhibitor in Phase 2 for idiopathic pulmonary fibrosis; as well as other investigational therapies such as GLPG1205 (a sphingosine-1-phosphate 1 receptor modulator), GLPG1690 (an autotaxin inhibitor), and earlier-stage assets targeting fibrosis and inflammation. Galapagos operates primarily in the biopharmaceutical sector, targeting patients with autoimmune diseases, inflammatory conditions, and fibrosis through small molecule therapeutics; its customer base includes healthcare providers, regulatory authorities, and strategic partners in the pharmaceutical industry. Founded in 1998 and headquartered in Mechelen, Belgium, the company conducts research and development across Europe and the United States, with manufacturing and clinical trial operations supported by contract organizations globally. In recent developments, Galapagos restructured its collaboration with Gilead Sciences in 2023, regaining full rights to filgotinib outside Europe and Asia while receiving a €330 million upfront payment and potential milestones; the company also advanced its fibrosis franchise by initiating the Phase 2 RESPIRO-IC trial for ziritaxestat in interstitial lung disease associated with systemic sclerosis in 2024 and reported positive interim data from the Phase 2 PINTA trial in systemic sclerosis; additionally, in 2025, Galapagos expanded its pipeline through a strategic alliance with a undisclosed partner for novel inflammatory targets and completed a €150 million financing round to support late-stage clinical programs.